Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD
ABVD
Hodgkin lymphoma
frontline intensification
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
28
05
2024
accepted:
04
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
2
8
2024
Statut:
aheadofprint
Résumé
We demonstrated that dose-densified and dose-intensified ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health, Ricerca Corrente
Organisme : IRCCS Istituto Nazionale Tumori - Fondazione Pascale
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Hanel W, Herrera AF, Epperla N. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Exp Hematol Oncol. 2022;11(1):108.
Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, et al. Long‐term follow‐up of the response‐adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2024;42(1):13–18.
Ansell SM, Radford J, Connors JM, Długosz‐Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab Vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med. 2022;387(4):310–320.
Herrera AF, LeBlanc ML, Castellino SM, Li H, Rutherford SC, Evens AM, et al. SWOG S1826, a randomized study of nivolumab(N)‐AVD versus brentuximab vedotin(BV)‐AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17_suppl):LBA4.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, et al. PET‐guided eBEACOPP treatment of advanced‐stage Hodgkin lymphoma (HD18): follow‐up analysis of an international, open‐label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e398–e409.
Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first‐line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomized trial by the German Hodgkin study group. Lancet Oncol. 2017;18(12):1680–1687.
Gibb A, Greystoke A, Ranson M, Linton K, Neeson S, Hampson G, et al. A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Br J Cancer. 2013;109(10):2560–2565.
Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, et al. A phase II study of dose‐dense and dose‐intense ABVD (ABVDDD‐DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014;166(1):118–129.
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. N Engl J Med. 2011;365(3):203–212.
Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. Five‐year follow‐up of SWOG S0816: limitations and values of a PET‐adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246.
Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response‐adapted therapy in advanced‐stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34(12):1376–1385.
Straus DJ, Dlugosz‐Danecka M, Connors JM, Alekseev S, Illes A, Picardi M, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON‐1): 5‐year update of an international, open‐label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410–e421.
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–214.
Belger C, Abrahams C, Imamdin A, Lecour S. Doxorubicin‐induced cardiotoxicity and risk factors. Int J Cardiol Heart Vasc. 2024;50:101332.
Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis. Cochrane Database Syst Rev. 2017;9(9):CD008814.
von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, et al. Intensive treatment strategies in advanced‐stage Hodgkin's lymphoma (HD9 and HD12): analysis of long‐term survival in two randomised trials. Lancet Haematol. 2018;5(10):e462–e473.
Pinto A, Corazzelli G, Evangelista A, Patti C, De Lorenzo S, Re A, et al. Frontline intensified ABVD demonstrates superior efficacy than PET‐adapted ABVD in advanced Hodgkin lymphoma: the FIL‐rouge phase 3 trial by the Fondazione Italiana Linfomi. Hematol Oncol. 2023;41(S2):31–33.